CSL Behring, a member of the CSL Group of companies and a leading global biotechnology company manufacturing plasma-based and recombinant therapeutic products, awarded WSP a contract to provide engineering services for the design and construction management of a new AU$210 million advanced manufacturing facility to increase its global production of albumin. Situated at its Broadmeadows site in Victoria, Australia the new facility would provide an additional manufacturing capacity of 200 tonnes annually to meet worldwide demand for this critical care product, and complement existing manufacturing facilities in Bern, Switzerland and Kankakee, Illinois, USA.
Following on from our successful delivery of its Turner Privigen® Facility, this project would encompass the delivery of a new three-story facility built over two phases for the commercial manufacture of AlbuRx®, a blood plasma-derived intravenous critical care therapy used to restore blood volume in patients in the treatment of severe burns, shock, pancreatitis, postoperative albumin loss, hypoproteinemia, liver failure, and more.
WSP would provide mechanical, hydraulics, fire protection and vertical transportation design services.
A highly responsive and experienced project team allowed for quick responses and tailored design and documentation solutions to suit CSL’s site-specific needs.
Our flexible and adaptive design team was able to effectively change the design during the construction phase to accommodate significant client-driven design changes in a time and cost effective manner.
The AlbuRx facility included the design of process chilled water and cooling water plant, plant steam systems, air handling systems to serve Grade C cleanrooms and integration with pharmaceutical process systems by GEA, Germany. A microbiology laboratory area and PC2 sterility laboratory suite is also located within the facility.